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Abstract 
Background 
Cognitive behaviour therapy (CBT) added to specialist medical care (SMC), or graded 
exercise therapy (GET) added to SMC, are more effective in reducing fatigue and improving 
physical function than both adaptive pacing therapy (APT) plus SMC and SMC alone for 
chronic fatigue syndrome (CFS). This paper investigates putative treatment mechanisms.  
Methods 
Mediation was assessed using the product of coefficients method with the 12 week measure 
of the mediators and the 52 week measure of the outcomes. Confounder covariates were 
included and treatment by mediator interaction terms were used to examine differences in 
mediator-outcome relationships by treatment group.  
Findings 
The largest mediated effect for both CBT and GET and both outcomes was through fear 
avoidance beliefs with an effect of larger magnitude for GET (standardised effects times 10, 
CBT v APT, fatigue -1·22, 95% CI = -0·52 to -1·97, physical function 1·54, CI = 0·86 to 
2·31; GET v APT, fatigue -1·86, CI = -0·80 to -2·89, physical function 2·35, CI = 1·35 to 
3·39). Increase in exercise tolerance (six minute walk distance) was a potent mediator of the 
effect of GET (v APT, fatigue -1·37, CI = -0·76 to -2·21, physical function 1·90, CI = 1·10, 
2·91), but not CBT.  
Interpretation 
Our main finding was that fear avoidance beliefs were the strongest mediator for both CBT 
and GET. Changes in both beliefs and behaviour mediated the effects of both CBT and GET, 
but more so for GET. The results support a treatment model in which both beliefs and 
behaviour play a role in perpetuating fatigue and disability in CFS.  
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Introduction  
Chronic fatigue syndrome (CFS), otherwise known as Myalgic Encephalomyelitis (ME) is 
associated with profound disability (1, 2). Our recent multi-centred randomised controlled 
trial (RCT), PACE (adaptive Pacing, graded Activity and Cognitive behaviour therapy; a 
randomised Evaluation) (3, 4), compared specialist medical care (SMC) alone versus SMC 
with adaptive pacing therapy (APT), cognitive behaviour therapy (CBT) or graded exercise 
therapy (GET) for CFS.  
 
We standardised treatments by the provision of manuals for doctors, therapists and 
participants (see www.pacetrial.org). At least 3 sessions of SMC were offered over 52 weeks 
and 14 hourly therapy sessions were offered weekly then fortnightly up to 24 weeks. A 
booster therapy session was given at 36 weeks. Specialist doctors gave participants general 
advice about managing the illness. It was suggested that extremes of activity and rest should 
be avoided, self-help books were suggested and specific pharmacotherapy could be offered 
for insomnia, pain or mood problems.  
 
CBT involves enabling individuals to develop a consistent approach to activity. This is 
followed by gradual increases in activity. CBT also encourages people to develop healthy 
sleep patterns and enables them to identify and challenge unhelpful cognitions (5) with the 
primary aims of reducing fatigue and improving physical function. It is based on a theoretical 
model which supposes that unhelpful interpretations of symptoms, fearful beliefs about 
engaging in activity, and excessive focus on symptoms are central in driving disability and 
symptom severity (5). These cognitive responses are associated with unhelpful behavioural 
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patterns, including avoidance of activity together with excessive rest, and all-or-nothing 
behaviour – a pattern of pushing too hard or being over-active when feeling well. 
 
GET for CFS involves establishing a baseline of consistent activity and regular sleep-wake 
cycle, then encouraging mutually negotiated increments in the time spent physically active 
(most commonly walking) followed by an incremental increase in the intensity of exercise to 
a target of  half an hour of physical exercise five times a week. It is based on a model of both 
de-conditioning (loss of muscle strength and reduced exercise capacity) and avoidance of 
activity (6). Both these factors are thought to maintain fatigue and disability (7-9). Systematic 
reviews have suggested that patients with CFS are less physically active and have less 
isometric muscle strength and reduced exercise capacity than healthy controls (10, 11). 
 
CBT and GET in the context of this trial had much in common, but could be differentiated. 
Both involved agreeing an achievable and consistent baseline of activity and then increasing 
activity, although GET specifically focused on physical exercise. CBT addressed unhelpful 
thoughts but GET did not. CBT and GET were clearly distinguished by independent raters 
who rated treatment integrity and were blind to treatment arm (3). 
 
APT for CFS involved encouraging participants to plan activity with a view to avoiding 
increases in symptoms, and limiting demands and stress. It included specific advice not to 
undertake activities that demanded more than 70% of participants’ perceived energy 
envelopes in order to establish a baseline of achievable activity, and then increasing as able 
(3). It was based on the envelope theory of chronic fatigue syndrome in which the illness is 
assumed to be entirely physical, with fixed energy levels (12).  
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We found that, when added to SMC, CBT and GET had greater success in reducing fatigue 
and physical disability than APT or SMC alone (3). The number of therapy sessions received 
was similar across groups. However the SMC alone group received a median of two more 
SMC sessions than the therapy supplemented treatment groups. Anti-depressant and hypnotic 
use did not differ significantly between groups, either at baseline or at follow-up. The interval 
between pre-treatment and follow up was the same. There were no important differences in 
safety outcomes between treatment options. Mean differences between groups on primary 
outcomes almost always exceeded predefined clinically useful differences for CBT and GET 
when compared with APT and SMC. In all comparisons of the proportions of participants 
who had either improved or were within normal ranges for these outcomes, CBT and GET 
were superior to APT or SMC alone (3). Improvements were moderate in size and therefore 
outcomes need to be improved further. Identifying mechanisms of change may elucidate 
ways in which effective treatments can be further developed, improved, or optimised. The 
study of mediation may also provide information about the utility of the model on which 
treatment is based.  
  
A couple of studies have examined potential treatment mechanisms in relation to GET. The 
first RCT of GET for CFS found that those who rated themselves as better were no fitter or 
stronger than the rest (13), but that better exercise tolerance was associated with being fitter 
(lower heart rate response to sub-maximal exercise) (8). A second trial of GET also suggested 
that physical reconditioning was not a mediator of the effect of treatment, but that a reduction 
in symptom focusing and increased exercise tolerance (as assessed by maximal heart rate 
achieved with exercise) mediated change in mental and physical fatigue (9).  
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There have been several studies of treatment mechanisms of CBT. Although a formal 
mediation analysis was not carried out, a reduction in fearful cognitions was associated with 
better outcomes in a trial of CBT compared to relaxation (14). More recently, Wiborg and 
colleagues found that a decrease in focusing on fatigue mediated the effect of CBT in one 
trial (15), while, in another trial, the effect of therapy was mediated by a decrease in 
perceived problems with activity and an increase in the sense of control over fatigue (16). 
These and other similar studies have relied on cross-sectional data (6, 8, 9, 14-17). 
Consequently, a temporal separation between the mediator and outcomes was missing, 
making it difficult to ascertain the direction of the causal relationship.  
 
The recent Fatigue Intervention by Nurses Evaluation (FINE) trial compared pragmatic 
rehabilitation to supportive listening or treatment as usual in CFS. Pragmatic rehabilitation 
contained elements of CBT and GET. It involved regular sessions with a health professional, 
and included physiological explanations for symptoms with graded activity but also ensured 
the individual had appropriate rest and relaxation. It was delivered at home, over an 18-week 
period by specially trained general nurses. A longitudinal mediation analysis found that 
reducing both catastrophising and avoidance of activity, measured immediately after the end 
of treatment, at 20 weeks, mediated a reduction in fatigue at 70 weeks follow up (18).  
 
We designed the PACE trial with an aim of gaining perspective on the mechanisms of change 
through the identification of mediators. To this end, the trial measured a range of putative 
mediators and outcomes. Our aims were:  
1) To explore whether specific putative mediators measured at 0, 12, 24 and 52 weeks 
changed to a different extent between treatment groups.  
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2) To examine whether these factors mediated differences in fatigue and physical function in 
CBT and GET compared to APT and SMC.  
 
Based on models of CFS and previous findings we hypothesized that fearful beliefs, in 
particular fear avoidance beliefs (e.g. ‘I am afraid that I will make my symptoms worse if I 
exercise’), symptom focusing (e.g. ‘I think a great deal about my symptoms’), catastrophising 
(e.g. ‘I will never feel right again’), and avoidance behaviour (e.g. ‘I stay in bed to control my 
symptoms’) would mediate change in fatigue and physical function in both CBT and GET. 
We also hypothesised that timed walking distance as a measure of exercise tolerance, but also 
as a more objective measure of activity engagement, would mediate change in both outcomes 
for CBT and GET. Based on the fact that embarrassment avoidance, damage beliefs, self-
efficacy, perception of effort and unhelpful sleep routines are targeted in CBT these 
additional processes were also examined. Some empirical evidence exists to support their 
inclusion. Embarrassment avoidance (e.g. ‘I am embarrassed about my symptoms’) and 
damage beliefs (e.g. ‘Symptoms are a signal that I am damaging myself’) have been shown to 
change with routine CBT and an exploratory latent trait model suggested that the observed 
partial mediation model generalized to illness-related cognitive traits (19). There is evidence 
that self-efficacy may be an important transdiagnostic mechanism of change (20, 21). 
Perception of effort with exercise is increased in people with CFS and we believed it was 
likely to change with rehabilitative treatments such as CBT and GET (13). A poor sleep 
routine is commonplace in people with CFS (22), and establishing a sleep routine is a focus 
of CBT and therefore may improve fatigue and disability. Finally on the basis of previous 
trials we predicted that anxiety, depression, all or nothing behaviour and fitness would not 
mediate treatment outcome either in CBT or GET.  
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Methods 
Design 
641 participants were recruited from consecutive new outpatients attending six specialist CFS 
clinics in the UK National Health Service. Participants fulfilled the Oxford criteria for CFS 
(2), which requires fatigue to be the principal symptom. All participants were medically 
assessed by the specialist clinic doctors to exclude alternative diagnoses (4). The West 
Midlands Multicentre Research Ethics Committee (MREC 02/7/89) approved the original 
PACE study. 
 
The main results of the trial have been reported elsewhere; 88% received an adequate dose of 
treatment and only 2% were completely lost to follow-up (3). We conducted a planned 
secondary mediation analysis of the PACE trial comparing SMC alone or SMC plus APT to 
SMC plus CBT and SMC plus GET for patients with chronic fatigue syndrome (3, 4).  
 
Description of the generic mediation model 
Mediation is a hypothesized causal chain in which a baseline variable R affects a post 
baseline mediating variable M, which in turn affects an outcome variable Y (23). In the case 
of a trial such as PACE, R is treatment group, for example CBT compared to APT, and an 
example mediator and outcome might be fear avoidance and physical function, as shown in 
Figure 1. If the intervening variable M explains the relationship between R and Y (the 
relationship between R and Y is no longer statistically significant when adjusting for M in the 
model and the estimate for R is essentially equal to zero), then M is a mediator and we have a 
full mediational model (24, 25). If the intervening variable only partially explains the 
relationship between R and Y (the M effect is statistically significant but R is not equal to 
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zero and/or still has a significant effect on Y after including M in the model) the model is 
consistent with partial but not full mediation (24, 25).  
 
Measures 
The measures, which are described in more detail in the web appendix, were all assessed at 0, 
12, 24 and 52 weeks after randomisation (except for the walk test, which was not done at 12 
weeks due to the anticipated burden for participants) and these were described using 
unadjusted mean profile plots. For the mediation analysis the 52 week measure of the 
outcome and the 12 week measure of the putative mediator were used. The 12 week measure 
of the mediator was used in order to capture change as early as possible and have the 
maximum possible separation between mediator and outcome measurements. This temporal 
separation between the variables was employed to meet the implicit mediation model 
assumption of ordering of the variables in the causal chain (23). Respecting this ordering is 
important for rendering causal mediation inferences more plausible. The exception was the 
walk test where the 24 week measure was used.  
 
The primary outcomes were fatigue measured by the Chalder fatigue scale and physical 
function measured by the physical function subscale of the SF-36. Several of the putative 
mediators were measured using the Cognitive Behavioural Responses Questionnaire 
(CBRQ); these were five cognitive measures: catastrophising, fear avoidance beliefs, damage 
beliefs, symptom focusing, and embarrassment avoidance beliefs, as well as two behavioural 
measures: all-or-nothing behaviour and avoidance/resting behaviour. Other putative 
mediators were: self-efficacy, sleep measured using the Jenkins Sleep Scale, anxiety and 
depression measured using the Hospital Anxiety and Depression Scale, fitness and perceived 
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exertion measured using a step test, and walking distance measured using the six-minute walk 
test. 
 
Statistical analysis 
The analyses were carried out using Stata, Version 10. The main outcomes were prorated 
only when there were at most two items missing from the scale. The mean value of complete 
item scores was calculated and used in place of missing scale values. The mediators were not 
prorated since most with missing data were missing all items. The main analyses, including 
regression models, were limited to participants with complete records for all variables 
considered. Mediators were summarised using the mean, standard deviation and 95% 
confidence interval for the mean. 
 
Mediation was assessed from regressions using the product of coefficients method (POC) 
(23),  shown in both equation (below) and path diagram form (Figure 1), where Y is the 
outcome, M is the mediator, R is randomised treatment group and ε is an error term (other 
covariates are not shown for simplicity): 
 
The β1 parameter is the overall effect of the treatment on the outcome, referred to as the c 
pathway in the mediation literature. The mediated (indirect) effect is then β2 multiplied by γ, 
or a multiplied by b from Figure 1. The direct effect of R on Y in the presence of M is given 
by β3 and is called the c’ pathway. In addition to the temporal ordering assumption mentioned 
in the Measures section, the usual assumptions are associated with the regressions used in the 
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POC method, including: accurate measurement, linearity, normally distributed residuals and 
no omitted variables (23). The latter assumption has received a great deal of attention 
recently in mediation, in particular in clinical trials where despite randomisation, there could 
still be confounding of the non-randomised relationship between the mediator and outcome 
(U in Figure 1) (23, 25, 26). If there are unmeasured variables that influence both mediator 
and outcome, the estimate obtained for this relationship may be biased. While unmeasured 
confounding cannot be ruled out, adding baseline variables that may be confounders makes a 
causal interpretation more plausible; further covariates were included in the models to 
address this (23, 26). For example, if these variables were confounders, including them will 
have provided an adjusted and hopefully more accurate estimate, and if they were proxies for 
unmeasured confounders they may have partially adjusted for the omitted variables as well. 
The variables were selected for inclusion in models because they were thought to be potential 
predictors of mediators and outcomes. Age and gender could also be proxies for other 
variables that were not measured. The original trial stratification factors were included in 
order to respect the trial design. The baseline variables were: centre, Standardised Clinical 
Interview for DSM-IV (SCID) depression status (27), London criteria for myalgic 
encephalomyelitis (ME) status (28), International criteria for CFS status (1), baseline measure 
of mediator, baseline measures of both outcomes, baseline work and social adjustment scale 
(29), any anxiety disorder as determined using the SCID, age, gender, CFS patient group 
membership, receipt of financial benefits, being in dispute regarding financial benefits, 
physical illness attribution, fibromyalgia status (30), illness duration, Jenkins sleep score, 
employment status, body mass index, and physical symptoms (Patient Health Questionnaire-
15) score (31). All of these variables were included in all models. Medication use variables 
were available, but were not used.  This was because these were not theorised to be likely 
confounders in the context of the large number of other confounders included.  
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The POC method shares some aspects with two other methods commonly applied to the study 
of mediation, the Baron-Judd-Kenny causal steps approach and the use of the structural 
equation model framework (23-25). The causal steps approach requires the overall treatment 
effect, or the effect of β1 in Model 1, to be significant before proceeding. Like others (23, 26) 
we do not believe this to be necessary. Rather, we suggest examining whether there is an 
absence of a treatment effect on the mediator, an absence of a mediator effect on the 
outcome, or the occurrence of opposing direct and indirect effects. The structural equation 
modelling framework requires some additional assumptions such as multivariate normality.  
 
The mediator models (Model 2) had the 12 week post-randomisation measurement of each of 
the putative mediators as the dependent variable (except for six minute walking distance 
where the 24 week measure was used) and both treatment arm and the potential confounders 
as covariates. The outcome models had the 52 week post-randomisation measure of each of 
the outcomes as the dependent variable, with treatment arm, the 12 week measure of the 
putative mediator and the potential confounders as covariates (Model 3). Tests of interaction 
between treatment and mediator on outcome were all non-significant, allowing a coefficient b 
to be estimated that was common to all treatments (see Figure 1), improving efficiency and 
model stability. The statistical significance and magnitude of the model parameters associated 
with the c and c’ pathways were used to assess whether mediation was partial or full.  
 
All continuous variables were standardised (each value had the mean of the variable 
subtracted and was divided by the standard deviation of the variable) so that parameters 
represented changes in standard deviation (SD) units. Results from the mediator models are 
therefore in SD units of the mediator; results from the outcome models are in SD units of the 
outcome. The a multiplied by b mediation effect here therefore constituted the recommended 
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standardised mediation effect in SD units of the outcome (23), with a bias-corrected bootstrap 
95% confidence interval. This allowed for asymmetry of the interval, obtained using 
bootstrapping with a thousand repetitions (23, 32). Bootstrap confidence intervals can have 
incorrect endpoints; the bias-corrected bootstrap adjusts the interval endpoints by a constant 
reflecting the approximate median bias of the bootstrap estimate in units of the standard 
normal distribution (32). All mediated effects were multiplied by 10 to decrease the number 
of decimal places in figures and tables for visualisation purposes. Mediated effects have also 
been expressed as the proportion of the overall effect of the treatment on the outcome, in 
other words (ab/c)*100. Note that the % mediated would not be expected to add up to 100% 
within a given comparison as the mediators have been studied individually and any 
overlapping effects have not yet been examined. Both CBT and GET were compared with 
APT and SMC separately. Some mediated effects have been compared between CBT and 
GET using Wald tests of the equality of the two parameter estimates in the mediator models 
(Model 2). 
 
Role of the funding source 
Neither the sponsors nor the funders of the study had any role in study design, data collection, 
data analysis, data interpretation, writing of the manuscript or the decision to publish the 
manuscript. 
 
Results 
Information on data completeness (Table A), balance of baseline variables between the 
treatment groups (Table B) in the mediation analysis data subset, and differences between the 
people with and without complete data for the mediation analysis (Table C) are available in 
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the web appendix. Unadjusted mean profile plots of the outcomes over time are also available 
in the Web appendix (Figure A). 
 
Pattern of change over time in variables used as mediators at 12 weeks  
Plots and summary statistics for the putative mediators (Figure 2 and Web appendix Table D) 
show similar patterns to those of the outcomes with greater improvement with CBT and GET, 
the majority of change occurring during the treatment phase. There was little change between 
the end of treatment at 24 weeks and follow up at 52 weeks. There were some exceptions to 
the general pattern; all or nothing behaviour decreased to a similar level for APT, CBT and 
GET, and fear avoidance improved more in the GET group than for CBT. 
 
Relationships between treatments and mediators  
Figure 3 shows the treatment effects of CBT and GET, as compared to APT and SMC, on the 
putative mediating variables. These effects equate to the a path shown in Figure 1 and are 
differences in mediator SD units between compared treatments. Compared to APT and SMC, 
both CBT and GET significantly decreased catastrophising, avoidance behaviour, fear 
avoidance beliefs and damage beliefs. The strongest effects were on fear avoidance beliefs 
(CBT v APT -0·64, 95%CI -0·46 to -0·83, GET v APT -0·98, 95% CI -0·80 to -1·16) and 
damage beliefs (CBT v APT -0·61, 95% CI -0·43 to -0·78, GET v APT -0·56, 95% CI -0·39 
to -0·73). GET had a larger effect on fear avoidance beliefs than did CBT (p < 0.001). 
Compared to APT, both CBT and GET decreased symptom focusing, and compared to SMC, 
the treatments significantly decreased all or nothing behaviour, sleep problems and increased 
self-efficacy. In addition, CBT also decreased symptom focusing, embarrassment avoidance 
and HADS depression as compared to SMC. In both types of comparisons, GET significantly 
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increased the number of metres walked while CBT did not (GET v APT 0·43, 95% CI 0·25 to 
0·61, GET v SMC 0·46, 95% CI 0·28 to 0·63, p for CBT versus GET = 0.001). There were 
no effects on HADS anxiety, physical fitness or the adjusted perception of effort measure 
(Borg scale). 
 
Relationships between mediators and outcomes  
Figure 4 shows the relationships between the putative mediators and the outcomes. These 
effects equate to the b path shown in Figure 1, and are differences in outcome SD units for a 
1 SD unit change in the mediator. The  models show that increases in catastrophising, all or 
nothing behaviour, embarrassment avoidance, fear avoidance beliefs, damage beliefs, HADS 
depression, sleep problems and Borg scores (=worsening) were associated with significantly 
worse fatigue, which means that when treatments reduced these variables, there was a 
reduction  in fatigue. Increases in (= better) scores of self-efficacy and metres walked were 
associated with significant decreases in fatigue. The strongest effects on fatigue were for 
metres walked and embarrassment avoidance (-0·32, 95% CI -0·20 to -0·44 and 0·27, 95% 
CI 0·16 to 0·38). All of the mediators with the exception of the physical fitness measure were 
associated with physical function, and similar to fatigue, these were in the directions 
expected. The largest effects here were for metres walked and HADS depression (0·44, 95% 
CI 0·34 to 0·55 and -0·33, 95% CI -0·23 to -0·43). Self-efficacy also had reasonably strong 
effects on both outcomes. 
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Mediation effects in PACE adjusting for potential confounders 
Figures 5 and 6 show standardised mediation effects (times 10) for all mediators and 
treatment comparisons studied (parameter estimates and confidence intervals and proportion 
mediated shown in Web appendix, Table E). Fear avoidance beliefs had the largest mediated 
effect on both fatigue and physical function for both CBT and GET (fatigue CBT v APT -
1·22, 95% CI -0·52 to -1·97, GET v APT -1·86, 95% CI -0·80 to -2·89, physical function 
CBT v APT 1·54, 95% CI 0·86 to 2·31, GET v APT 2·35, 95% CI 1·35 to 3·39). This 
accounted for 51% of the overall effect on physical function for GET and 37% for CBT, as 
compared to APT. The proportions were 61% and 34% for the same comparisons for the 
fatigue outcome. Damage beliefs also mediated the effects of both treatments on both 
outcomes – the effects were the second largest in magnitude of the cognitive mediators for 
comparisons with APT (fatigue CBT v APT -0·85, 95% CI -0·23 to -1·68, GET v APT -0·78, 
95% CI -0·24 to -1·58, physical function CBT v APT 1·26, 95% CI 0·61 to 2·13, GET v 
APT 1·16, 95% CI 0·57 to 2·02), with approximately 25 – 30 % of the overall effect on both 
outcomes being accounted for by damage beliefs. Damage beliefs and self-efficacy were 
mediators of similar magnitude for the SMC comparisons. For comparisons with APT, self-
efficacy was either a relatively weak or non-significant mediator because it didn’t change 
significantly more with either CBT or GET than with APT (Figure 3). Catastrophising and 
avoidance behaviour were also significant mediators of treatments for all comparisons and 
both outcomes, albeit with effects of smaller magnitude as compared to fear avoidance 
(Figures 5 and 6 and Web appendix Table E). For example, the largest proportion of the 
overall effect explained for catastrophising was 18% for CBT versus APT for the physical 
function outcome. The number of metres walked (exercise tolerance) was a strong mediator 
of the effect of GET on both outcomes, both for comparisons to APT and SMC (fatigue GET 
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v APT -1·37, 95% CI -0·76 to -2·21, GET v SMC -1·46, 95% CI -0·75 to -2·34, physical 
function GET v APT 1·90, 95% CI 1·10 to 2·91, GET v SMC 2·03, 95% CI 1·16 to 2·99), 
with this accounting for approximately 33% of the overall effect for the comparisons to APT. 
Other mediated effects which were statistically significant for both outcomes were 
embarrassment avoidance for CBT for both comparisons, all or nothing behaviour and sleep 
problems for CBT and GET comparisons to SMC and depression for CBT versus SMC only. 
One mediating effect was limited to the outcome of physical function: symptom focusing was 
a mediator of CBT as compared to both APT and SMC. Figure 7 shows example path 
diagrams for the fear avoidance beliefs mediator. Fear avoidance was a partial rather than a 
full mediator in both cases. This can be seen by looking at the c’ path, or residual direct effect 
of treatment. This path was only non-significant for the GET v APT comparison for the 
physical function outcome, and even so it still differs substantially from zero. 
 
The analysis was repeated using the full information maximum-likelihood structural equation 
modelling framework that required the weaker assumption of data missing at random and 
allowed for loss selective on covariates and measured outcomes as described in the Methods 
(35). The effective sample sizes were increased to: 613 to 617 for questionnaire measures (up 
to 96% complete), 534 for fitness (83% complete), 535 for perceived exertion (Borg, 84% 
complete) and 595 for walking (93% complete). Results remained essentially unchanged, 
though some effects that were not significant but borderline in the original analysis became 
significant: walking for CBT versus SMC, symptom focusing for GET versus APT and 
physical function and depression for GET versus SMC for fatigue.  
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Discussion 
Our main finding was that fear avoidance beliefs were the strongest mediator for both CBT 
and GET. Fear avoidance beliefs are characterised by fears that activity or exercise will make 
symptoms worse. Damage beliefs were also important in comparison with APT. Exercise 
tolerance as measured by the number of metres walked in a fixed time was a strong mediator 
of GET alone. Other cognitive and behavioural measures, such as catastrophising and 
avoidance behaviour, had small but significant mediation effects for both of the effective 
treatments affecting both outcomes.  
 
The results suggest that GET may be more specific in its effects than CBT, with two strong 
mediators, fear avoidance beliefs and timed walking distance. The increase in exercise 
tolerance (walking distance) without an increase in exercise capacity (fitness) may have been 
facilitated by the mediating effect of reduced fear avoidance beliefs.  This is in keeping with 
the findings of increased exercise tolerance in a previous trial (9).  
 
For CBT, several mediators were implicated with smaller effects of similar magnitude, 
including depression for comparisons to SMC. Although we are cautious about over 
interpreting the role of depression as a mediator, CBT is an evidence based approach for 
depression which comprises a variety of different procedures including behavioural activation 
and cognitive restructuring not dissimilar to CBT for CFS.  
 
Fear avoidance beliefs, the strongest mediator, accounted for up to 60% of the overall effect, 
providing evidence for partial mediation. Many of the mediators accounted for much smaller 
proportions of the overall effects.  This suggests that in some cases the effects of treatment on 
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outcomes may have been mediated through several small effects and that some of the overall 
treatment effects were mediated through variables that were not measured.  
 
These findings, which benefit from temporal separation in mediator and outcome measures, 
support the preliminary findings of previous studies in CFS (14, 18). Deale et al (1998) found 
avoidance behaviour was a mediator of the effect of CBT on physical function cross-
sectionally (14). Recently, the mediation analysis of the FINE trial of pragmatic rehabilitation 
found that embarrassment avoidance, all or nothing and avoidance behaviour were cross-
sectional mediators of the treatment effect (18), whereas catastrophising and avoidance 
behaviour were prospective mediators of the effect on fatigue.  
 
Symptom focusing was found to be a cross-sectional mediator of CBT and GET on fatigue in 
two previous studies (9, 15), was not a mediator of the effect of the pragmatic rehabilitation 
treatment in the FINE trial (18) and only a weak mediator of the effect of CBT on physical 
function in our study. These dissimilar results could be explained by differences in the 
measurement of symptom focusing, due to the fact that the mediators were assessed in a 
cross-sectional fashion in the previous studies, or due to differences in treatment protocols.  
 
Wiborg and colleagues found perception of activity and an increase in sense of control were 
mediators of the effect of CBT on fatigue, which is similar to our findings (16). Fitness and 
perception of exertion did not appear to mediate the effect of CBT or GET here, a finding 
consistent with previous studies (8, 9, 18). Our study is the first to assess differences in timed 
walking distance. This was found to mediate the effect of GET, suggesting that increasing 
tolerance of physical activity may produce benefit without improving physical fitness. 
However, it must be acknowledged that the walking test might not reflect activity or exercise 
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levels in everyday life and may provide an explanation for why Wiborg et al (2010) found no 
evidence that actometer-measured physical activity mediated the effect of CBT (17). 
 
This mediational analysis strengthens the validity of our theoretical model of CBT and 
supports the idea that a similar model is valid for GET by confirming the role of fearful 
beliefs and avoidance behaviour. The review of beliefs in CFS and fibromyalgia (33), 
suggested that fear and avoidance of movement were related to poorer outcomes. This fits 
with findings from a previous study which showed that fear avoidance beliefs partially 
mediated the relationship between avoidance behaviour and treatment outcomes at six 
months following CBT (19). The results in the current paper support these findings 
suggesting that fearful beliefs can be changed by directly challenging such beliefs (as in 
CBT) or by simple behaviour change with a graded approach to the avoided activity (as in 
GET).  
 
Clinically, the results suggest that therapists delivering CBT could encourage more physical 
activities such as walking. This may enhance the effect of CBT and may be more acceptable 
to patients. Previous feedback from young people with CFS suggested that they liked the 
behavioural aspects of CBT, but did not like cognitive restructuring (34).  
 
The strengths of this study are that the results originate from the largest trial of CBT and GET 
to date. The study had few drop-outs and adherence to treatment was high. The study of 
mediation was incorporated at the design stage of PACE, so mediators were measured at mid-
treatment allowing the study of mediator measurements taken prior to those of the outcomes. 
Temporal ordering of variables and the inclusion of many potential confounding variables 
makes causal inferences about the mediated effects more plausible. Both self-report and 
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objective measures were used, and both were found to mediate treatment effects, lending 
credence to the results.  
 
Limitations include the issue of potential residual unmeasured confounding of the mediator to 
outcome path. However, given that adjustment was made for several potential confounders it 
seems unlikely that residual confounding could explain the mediation effects found, 
especially for the stronger effects. It is possible that variables were measured with error; 
however, this generally leads to the dampening of effects and so would have disguised a 
variable’s mediating effect rather than leading to a variable being found to be a mediator in 
error. This was a complete case analysis, requiring an assumption of missing completely at 
random, which was a greater concern for the step and walk-test mediators, where more data 
was missing, than for the questionnaire-based mediators. However, the results of the full 
information maximum-likelihood analysis did not differ greatly from the complete case 
analysis, suggesting serious missing data biases were unlikely. 
 
In an ideal world mediators would have been assessed at every session. Given the pattern of 
change in the mediators was similar to the pattern of change in the outcomes it is possible 
that the variables were influencing each other reciprocally and more measures might have 
helped clarify this. However, this was prohibitive in this trial due to cost and possible 
measurement fatigue on the patients’ part. Results from longitudinal analyses incorporating 
all available mediator and outcome measurements will be discussed in future publications. In 
addition, we were only able to assess walking at 24 weeks when most of the change in 
outcomes had occurred. It would have been more convincing as a mediator if it had been 
assessed at 12 weeks mid treatment. We didn’t find evidence of differing b paths 
(relationships between the mediators and outcomes) by treatment group, but we may have 
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had limited power to test for these interactions. Given the number of mediators that have been 
considered it is possible that some of the findings could be due to chance, in other words, 
type 1 errors may have been made.  This should be kept in mind in interpreting the findings, 
in particular for the more exploratory mediators. Finally, in this paper we focused on single 
mediators and the effects of some of these variables are not likely to be independent. Our 
forthcoming analysis of multiple mediator effects will provide more information on this 
issue.  
 
Conclusions 
CBT and GET treatments appear to work mainly through common mechanisms, changing 
fear avoidance beliefs. CBT and GET do not work by improving fitness or by decreasing 
perception of effort, nor do they work by reducing anxiety. However, GET increased exercise 
tolerance, as compared to APT or SMC, indicating that a change in behaviour in the absence 
of a direct focus on changing beliefs can improve both fatigue and physical function.  
Mediation of the treatment effect was partial which means that part of the treatment response 
remains unexplained. Multiple mediator analysis will provide more information about the 
degree to which the different mediators exert independent effects. These findings are 
clinically relevant.  They provide evidence for the mechanisms of change in treatment and 
demonstrate that CBT and GET work primarily in similar ways i.e. by changing fear 
avoidance beliefs. Future studies should focus on improving self-efficacy and increasing 
physical activity as these identified mediators had strong relationships with the outcomes.  
This may lead to greater improvements in outcomes.   
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Panel 1: Research in context 
Systematic review 
For the adaptive Pacing, graded Activity and Cognitive behaviour therapy; a 
randomised Evaluation (PACE) trial, PubMed and Cochrane Library databases were 
searched up to November 6, 2010, and the detailed findings of this are in the Research 
in Context box in the primary trial publication (3). This review concluded that 
cognitive behaviour therapy (CBT) and graded exercise therapy (GET) were 
moderately effective treatments for chronic fatigue syndrome (CFS), and the results of 
the PACE trial agreed with this (3). There have been few papers published on 
mediation of treatment effects in CFS, so these were found through pre-existing 
knowledge of publications, reference lists in these publications and in the course of 
routine searches for publications in the field using PubMed up to May 28, 2014. There 
is an early paper formulating a general model for fatigue in a group of patients with 
CFS (6). There are also several studies using cross-sectional mediator and outcome 
data to study either mediation or relationships between mediators and outcomes for 
CBT (14-17) and for GET (9, 13). The recent mediation analysis of the FINE trial of 
pragmatic rehabilitation for CFS used longitudinal data to study mediation (18). In 
cross-sectional studies, both CBT and GET were found to target cognitive measures 
such as fear of, and perceived problems with, activity, symptom focusing, and self-
efficacy (9, 14-16). Fitness measures did not mediate the effects of the treatments (9, 
17). The FINE trial showed both cognitive (catastrophising) and behavioural 
(avoidance behaviour) variables to be longitudinal mediators of the relationship 
between pragmatic rehabilitation and fatigue (18). 
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Interpretation 
Given that the PACE trial showed moderate effects of CBT and GET treatments, it 
was of interest to understand through which variables these overall effects were 
mediated. We confirm that fear avoidance beliefs partially mediate the effects of CBT 
and GET on physical function and fatigue outcomes, and that fitness measures do not 
appear to mediate the effects of either treatment. We have also shown that changes in 
behaviour, i.e. increased walking distance and reduced avoidance behaviour, can also 
transmit the effects of treatments to the outcomes, in particular walking distance for 
GET. We did not find much evidence for symptom focusing as a mediator in this 
study. These findings from longitudinal data respecting the hypothesised causal 
ordering of mediators and outcomes are likely more robust than those from past 
studies using cross-sectional data. In addition, we identified mediators with strong 
relationships with outcomes, self-efficacy and walking distance; if treatments for CFS 
could be refined to target these mediators to a greater extent they may effect greater 
improvements in outcomes.  
 
 
Author contributions 
The PACE trial co-principal investigators were PW, TC and MS. TC conceived of and 
designed the clinical aspect of this study of mediation with contributions from PW and MS. 
KG designed and completed the statistical analysis. The manuscript was written by TC, KG, 
PW and MS. AP consulted on the statistical analysis and interpretation of the results. 
 
26 
 
Acknowledgements 
Funding for the PACE trial was provided by the Medical Research Council, Department for 
Health for England, The Scottish Chief Scientist Office, and the Department for Work and 
Pensions. TC, AP and KG were in part supported by the NIHR Biomedical Research Centre 
for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of 
Psychiatry, Kings College London. KG was also funded by an NIHR Doctoral Fellowship. 
We acknowledge the help of the PACE Trial Management Group, which consisted of the 
authors of this paper, excluding AP, plus (in alphabetical order): H. Baber, J. Bavinton, M. 
Burgess, L. V. Clark, D. L. Cox, J. C. DeCesare, E. Feldman, P. McCrone, G. Murphy, M. 
Murphy, H. O’Dowd, T. Peto, L. Potts, R. Walwyn, and D. Wilks. 
Conflicts of interest 
PDW has done voluntary and paid consultancy work for the United Kingdom government 
and a reinsurance company. TC has received royalties from Sheldon Press and Constable and 
Robinson. MS has done voluntary and paid consultancy work for the United Kingdom 
government, has done consultancy work for an insurance company, and has received royalties 
from Oxford University Press. KG and AP have no conflicts of interest to declare. 
Disclaimer 
This report is independent research partly arising from a Doctoral Research Fellowship 
supported by the National Institute for Health Research. The views expressed in this 
publication are those of the author(s) and not necessarily those of the NHS, the National 
Institute for Health Research or the Department of Health. 
27 
 
References 
1. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al. 
Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition 
and recommendations for resolution. BMC health services research. 2003;3(1):25. Epub 
2004/01/02. 
2. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, et al. 
A report--chronic fatigue syndrome: guidelines for research. Journal of the Royal Society of 
Medicine. 1991;84(2):118-21. Epub 1991/02/01. 
3. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. 
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise 
therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. 
Lancet. 2011;377(9768):823-36. Epub 2011/02/22. 
4. White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R. Protocol for the PACE 
trial: a randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and 
graded exercise, as supplements to standardised specialist medical care versus standardised 
specialist medical care alone for patients with the chronic fatigue syndrome/myalgic 
encephalomyelitis or encephalopathy. BMC Neurol. 2007;7:6. Epub 2007/04/03. 
5. Burgess M, Andiappan M, Chalder T. Cognitive Behaviour Therapy for Chronic 
Fatigue Syndrome in Adults: Face to Face versus Telephone Treatment - A Randomized 
Controlled Trial. Behav Cogn Psychoth. 2012;40(2):175-91. 
6. Vercoulen JH, Swanink CM, Galama JM, Fennis JF, Jongen PJ, Hommes OR, et al. 
The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: development of 
a model. J Psychosom Res. 1998;45(6):507-17. Epub 1998/12/22. 
28 
 
7. Clark LV, White PD. The role of deconditioning and therapeutic exercies in chronic 
fatigue syndrome (CFS). JMH. 2005;14(3):237-52. 
8. Fulcher KY, White PD. Strength and physiological response to exercise in patients 
with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2000;69(3):302-7. Epub 
2000/08/17. 
9. Moss-Morris R, Sharon C, Tobin R, Baldi JC. A randomized controlled graded 
exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. J Health 
Psychol. 2005;10(2):245-59. Epub 2005/02/23. 
10. Nijs J, Aelbrecht S, Meeus M, Van Oosterwijck J, Zinzen E, Clarys P. Tired of being 
inactive: a systematic literature review of physical activity, physiological exercise capacity 
and muscle strength in patients with chronic fatigue syndrome. Disabil Rehabil. 2011;33(17-
18):1493-500. 
11. Evering RM, van Weering MG, Groothuis-Oudshoorn KC, Vollenbroek-Hutten MM. 
Daily physical activity of patients with the chronic fatigue syndrome: a systematic review. 
Clinical rehabilitation. 2011;25(2):112-33. Epub 2010/10/15. 
12. Pesek JR, Jason LA, Taylor RR. An empirical investigation of the envelope theory. J 
Hum Behav Soc Environ. 2000;3(1):59-77. 
13. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients 
with the chronic fatigue syndrome. BMJ. 1997;314(7095):1647-52. Epub 1997/06/07. 
14. Deale A, Chalder T, Wessely S. Illness beliefs and treatment outcome in chronic 
fatigue syndrome. J Psychosom Res. 1998;45(1):77-83. Epub 1998/08/28. 
15. Wiborg JF, Knoop H, Prins JB, Bleijenberg G. Does a decrease in avoidance behavior 
and focusing on fatigue mediate the effect of cognitive behavior therapy for chronic fatigue 
syndrome? J Psychosom Res. 2011;70(4):306-10. 
29 
 
16. Wiborg JF, Knoop H, Frank LE, Bleijenberg G. Towards an evidence-based treatment 
model for cognitive behavioral interventions focusing on chronic fatigue syndrome. Journal 
of Psychosomatic Research. 2012;72(5):399-404. 
17. Wiborg JF, Knoop H, Stulemeijer M, Prins JB, Bleijenberg G. How does cognitive 
behaviour therapy reduce fatigue in patients with chronic fatigue syndrome? The role of 
physical activity. Psychol Med. 2010;40(8):1281-7. 
18. Wearden AJ, Emsley R. Mediators of the Effects on Fatigue of Pragmatic 
Rehabilitation for Chronic Fatigue Syndrome. J Consult Clin Psychol. 2013. Epub 
2013/06/26. 
19. Stahl D, Rimes KA, Chalder T. Mechanisms of change underlying the efficacy of 
cognitive behaviour therapy for chronic fatigue syndrome in a specialist clinic: a mediation 
analysis. Psychol Med. 2013:1-14. Epub 2013/08/13. 
20. Stanton AL, Luecken LJ, MacKinnon DP, Thompson EH. Mechanisms in 
Psychosocial Interventions for Adults Living With Cancer: Opportunity for Integration of 
Theory, Research, and Practice. Journal of consulting and clinical psychology. 
2013;81(2):318-35. 
21. Turner JA, Holtzman S, Mancl L. Mediators, moderators, and predictors of 
therapeutic change in cognitive-behavioral therapy for chronic pain. Pain. 2007;127(3):276-
86. 
22. Fossey M, Libman E, Bailes S, Baltzan M, Schondorf R, Armsel R, et al. Sleep 
quality and psychological adjustment in chronic fatigue syndrome. J Behav Med. 
2004;27(6):581-605. 
23. MacKinnon DP. Introduction to Statistical Mediation Analysis. Harlow L, editor: 
Taylor & Francis Group LLC; 2008. 
30 
 
24. Baron RM, Kenny DA. The moderator-mediator variable distinction in social 
psychological research: conceptual, strategic, and statistical considerations. J Pers Soc 
Psychol. 1986;51(6):1173-82. Epub 1986/12/01. 
25. Judd CM, Kenny DA. Process Analysis - Estimating Mediation in Treatment 
Evaluations. Evaluation Review. 1981;5(5):602-19. 
26. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in 
randomised controlled trials of complex interventions. Stat Methods Med Res. 
2010;19(3):237-70. Epub 2009/07/18. 
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for 
DSM-IV-TR, Research Version, Patient Edition With Psychotic Screen. New York, NY: 
2002. 
28. National Task Force. Report on Chronic Fatigue Syndrome (CFS), Post Viral Fatigue 
Syndrome (PVFS) and Myalgic Encephalomyelitis (ME). Bristol, UK: 1994. 
29. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: 
a simple measure of impairment in functioning. Brit J Psychiat. 2002;180:461-4. 
30. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. 
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. 
Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-72. Epub 
1990/02/01. 
31. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a new measure for 
evaluating the severity of somatic symptoms. Psychosomatic Medicine. 2002;64(2):258-66. 
32. Efron B, Tibshirani R. An Introduction to the Bootstrap. Boca Raton, FL: Chapman 
and Hall/CRC; 1993. 
33. Nijs J, Roussel N, Van Oosterwijck J, De Kooning M, Ickmans K, Struyf F, et al. Fear 
of movement and avoidance behaviour toward physical activity in chronic-fatigue syndrome 
31 
 
and fibromyalgia: state of the art and implications for clinical practice. Clinical 
rheumatology. 2013. Epub 2013/05/04. 
34. Dennison L, Stanbrook R, Moss-Morris R, Yardley L, Chalder T. Cognitive 
behavioural therapy and psycho-education for chronic fatigue syndrome in young people: 
Reflections from the families' perspective. Brit J Health Psych. 2010;15:167-83. 
35. Enders CK, Bandalos DL. The Relative Performance of Full Information Maximum 
Likelihood Estimation for Missing Data in Structural Equation Models. Struct Equ Modeling. 
2001;8(3):430-57. 
 
 
32 
 
Figures 
Figure 1. Example of a PACE mediation model 
 
*For example, CBT versus APT 
R = randomised treatment, M = mediator, Y = outcome, U = unmeasured confounders, a = a path (treatment to mediator), b 
= b path (mediator to outcome), c’ = c’ path (direct effect of treatment on outcome accounting for mediator), e2 = error term 
in mediator model, e3 = error term in outcome model 
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Figure 2. Unadjusted mean (95% CI) of putative mediator measures over time 
APT= adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist 
medical care. For mediation analysis, baseline measurements were used as covariates and 12 week measurements were used 
as mediators. 
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Figure 3. Standardised effects of treatments on putative mediators in SD units of the mediator* 
 
*As well as treatment, models also included: centre, SCID depression status, London criteria for ME status, International criteria for CFS status, baseline measures of both outcome variables, 
baseline WSAS, SCID anxiety disorder status, age, gender, CFS group membership, receipt of benefits, benefits in dispute, physical illness attribution, fibromyalgia status, illness duration, 
Jenkins sleep score, employment status, body mass index and physical symptoms (PHQ-15) score. 
B = standardised beta parameter from model for mediator, CI = confidence interval, APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = 
specialist medical care, Catas = catastrophising, Sym Foc = symptom focusing, Avoid Beh = avoidance behaviour, All or Noth = all or nothing behaviour, Emb Av = embarrassment avoidance 
beliefs, Fear A = fear avoidance beliefs, Damage = damage beliefs, Self-Eff = self-efficacy, HAD = Hospital Anxiety and Depression Scale, Dep = HADS depression subscale, Anx = HADS 
anxiety subscale, Sleep = Jenkins Sleep Scale, Borg = adjusted Borg scale 
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Figure 4. Standardised effects of putative mediators on outcomes in SD units of the outcome 
* 
 
*As well as treatment, models also included: centre, SCID depression status, London criteria for ME status, International 
criteria for CFS status, baseline measures of both outcome variables, baseline WSAS, SCID anxiety disorder status, age, 
gender, CFS group membership, receipt of benefits, benefits in dispute, physical illness attribution, fibromyalgia status, 
illness duration, Jenkins sleep score, employment status, body mass index and physical symptoms (PHQ-15) score. 
B = standardised beta parameter from model for outcome, CI = confidence interval, APT = adaptive pacing therapy, CBT = 
cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care, Catas = catastrophising, Sym 
Foc = symptom focusing, Avoid Beh = avoidance behaviour, All or Noth = all or nothing behaviour, Emb Av = 
embarrassment avoidance beliefs, Fear Av = fear avoidance beliefs, Damage = damage beliefs, Self-Eff = self-efficacy, 
HAD = Hospital Anxiety and Depression Scale, dep = HADS depression subscale, anx = HADS anxiety subscale, Sleep = 
Jenkins Sleep Scale, Borg = adjusted Borg scale 
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Figure 5. Standardised mediation effects in SD units of the outcome (times 10) of treatments on fatigue* 
*As well as treatment, models also include: centre, SCID depression status, London criteria for ME status, International criteria for CFS status, baseline measures of both outcome variables, 
baseline WSAS, SCID anxiety disorder status, age, gender, CFS group membership, receipt of benefits, benefits in dispute, physical illness attribution, fibromyalgia status, illness duration, 
Jenkins sleep score, employment status, body mass index and physical symptoms (PHQ-15) score. 
CI = confidence interval, APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care, Catas = catastrophising, Sym Foc 
= symptom focusing, Avoid Beh = avoidance behaviour, All or Noth = all or nothing behaviour, Emb Av = embarrassment avoidance beliefs, Fear Av = fear avoidance beliefs, Damage = 
damage beliefs, Self-Eff = self-efficacy, HAD = Hospital Anxiety and Depression Scale, dep = HADS depression subscale, anx = HADS anxiety subscale, Sleep = Jenkins Sleep Scale, Borg = 
adjusted Borg scale 
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Figure 6. Standardised mediation effects in SD units of the outcome (times 10) of treatment on physical function*  
*As well as treatment, models also include: centre, SCID depression status, London criteria for ME status, International criteria for CFS status, baseline measures of both outcome variables, 
baseline WSAS, SCID anxiety disorder status, age, gender, CFS group membership, receipt of benefits, benefits in dispute, physical illness attribution, fibromyalgia status, illness duration, 
Jenkins sleep score, employment status, body mass index and physical symptoms (PHQ-15) score. 
CI = confidence interval, APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care, Catas = catastrophising, Sym Foc 
= symptom focusing, Avoid Beh = avoidance behaviour, All or Noth = all or nothing behaviour, Emb Av = embarrassment avoidance beliefs, Fear Av = fear avoidance beliefs, Damage = 
damage beliefs, Self-Eff = self-efficacy, HAD = Hospital Anxiety and Depression Scale, dep = HADS depression subscale, anx = HADS anxiety subscale, Sleep = Jenkins Sleep Scale, Borg = 
adjusted Borg scale 
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Figure 7. Standardised effects in mediation models through fear avoidance in SD units of the outcome 
 
*As well as treatment, models also include: centre, SCID depression status, London criteria for ME status, International criteria for CFS status, baseline measures of both outcome variables, 
baseline WSAS, SCID anxiety disorder status, age, gender, CFS group membership, receipt of benefits, benefits in dispute, physical illness attribution, fibromyalgia status, illness duration, 
Jenkins sleep score, employment status, body mass index and physical symptoms (PHQ-15) score. 
e2, e3 = model error terms, APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care, FA = fear avoidance beliefs 
 
 
